Loading... Please wait... Loading... Please wait...
ESTIMATED
08/05/2020
08/05/2020
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 0 | $1.58 | $1.58 | $1.58 |
| Q2 2024 | 0 | $1.34 | $1.34 | $1.34 |
| Q3 2024 | 0 | $1.54 | $1.54 | $1.54 |
ARCA biopharma, Inc. last posted its earnings results on Wednesday, August 5th, 2020. The company reported $-0.73 earnings per share for the quarter, topping analysts' consensus estimates of $-2.58 by $1.85. The company had revenue of 0 for the quarter and had revenue of 0 for the year. ARCA biopharma, Inc. has generated $0 earnings per share over the last year ($-0.37 diluted earnings per share) and currently has a price-to-earnings ratio of -9.1. ARCA biopharma, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Friday, July 19th, 2024 based on prior year's report dates.
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue | 04/25/2024 | Q4 2023 | -$0.14 | $0 | $0 | 02/01/2024 | Q3 2023 | -$0.08 | $0 | $176,000 | 10/18/2023 | Q2 2023 | -$0.10 | $0 | 07/21/2023 | Q1 2023 | -$0.07 | $0 | 04/24/2023 | Q4 2022 | -$0.06 | $0 | 02/24/2023 | Q3 2022 | -$0.06 | $0 | 10/28/2022 | Q2 2022 | -$0.15 | $0 | 08/02/2022 | Q1 2022 | -$0.22 | $0 | 05/02/2022 | Q4 2021 | -$0.23 | $0 | 03/14/2022 | Q3 2021 | -$0.39 | $0 | 11/02/2021 | Q2 2021 | -$0.33 | $0 | 08/04/2021 | Q1 2021 | -$0.34 | $0 | 05/11/2021 | Q4 2020 | -$0.33 | $0 | 03/18/2021 | Q3 2020 | -$0.41 | $0 | 11/02/2020 | Q2 2020 | -$0.33 | $0 | 08/05/2020 | Q1 2020 | -$2.58 | -$0.73 | 1.85 | $0 | 05/06/2020 | Q4 2019 | -$2.04 | -$0.83 | 1.21 | $0 | 02/18/2020 | Q3 2019 | -$0.99 | -$0.77 | 0.22 | $0 | 11/06/2019 | Q2 2019 | -$1.30 | -$0.76 | 0.54 | $0 | 08/01/2019 | Q1 2019 | -$1.86 | -$1.14 | 0.72 | $0 |
|---|
A. ARCA biopharma, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Friday, July 19th, 2024 based off last year's report dates.
A. In the previous quarter, ARCA biopharma, Inc. (NASDAQ:ABIO) reported $-0.73 earnings per share (EPS) to beat the analysts' consensus estimate of $-2.58 by $1.85.
A. The conference call for ARCA biopharma, Inc.'s latest earnings report can be listened to online.
A. The conference call transcript for ARCA biopharma, Inc.'s latest earnings report can be read online.
A. ARCA biopharma, Inc. (NASDAQ:ABIO) has a recorded net income of $0. ARCA biopharma, Inc. has generated $-0.37 earnings per share over the last four quarters.
A. ARCA biopharma, Inc. (NASDAQ:ABIO) has a price-to-earnings ratio of -9.1 and price/earnings-to-growth ratio is -0.22.
